BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

  December 10, 2024

   · 

  28 min read
• Press Releases

  Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

  December 10, 2024

   · 

  14 min read
• Press Releases

  CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study

  December 10, 2024

   · 

  29 min read
• Press Releases

  RenaissThera Closes Seed Funding to Drive AI-Powered Therapies for Cardio-Metabolic Diseases

  December 10, 2024

   · 

  1 min read
• Press Releases

  Protara Announces Pricing of $100 Million Public Offering

  December 10, 2024

   · 

  4 min read
• Press Releases

  New and updated data for Roche’s fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

  December 10, 2024

   · 

  12 min read
• Press Releases

  CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference

  December 10, 2024

   · 

  4 min read
• Press Releases

  7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline

  December 10, 2024

   · 

  1 min read
• Press Releases

  CEPI and Accumulus Synergy team up to enhance information equity and accelerate access to vaccines

  December 10, 2024

   · 

  4 min read
• Press Releases

  IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

  December 10, 2024

   · 

  4 min read